epic3: revised recommendation for intravenous catheter and catheter site care by Loveday, HP et al.
This is an author produced version of epic3: revised recommendation for intravenous 
catheter and catheter site care.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/111873/
Article:
Loveday, HP, Wilson, JA, Prieto, J et al. (1 more author) (2016) epic3: revised 
recommendation for intravenous catheter and catheter site care. Journal of Hospital 
Infection, 92 (4). pp. 346-348. ISSN 0195-6701 
https://doi.org/10.1016/j.jhin.2015.11.011
(c) 2015, Published by Elsevier Ltd on behalf of the Healthcare Infection Society. This 
manuscript version is made available under the CC BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
  
 
Sir,  
In parallel with the NICE MTG review of Tegaderm 2% chlorhexidine (CHG) 
gel impregnated dressing (NICE, 2015)1, the Epic3 scientific advisors 
reviewed the evidence and wording of the recommendation relating to the use 
of  CHG impregnated dressings (Loveday et al 2014)2 which currently states: 
 
IVAD 20 "Consider the use of a chlorhexidine impregnated sponge dressing in 
adult patients with a central venous catheter as a strategy to reduce catheter 
related bloodstream infection."  New recommendation ClDVV%´ 
  
Following a review of the evidence3,4 the Guideline Development Group 
(GDG) has revised the recommendation to include 2% CHG gel impregnated 
dressings in addition to 2% CHG impregnated sponge dressings. 
 
Revised Evidence Summary 
 
Catheter and Catheter Site Care  
 
Infections can be minimised by good catheter and insertion site care  
The safe maintenance of an intravascular catheter and appropriate care of the 
insertion site are essential components of a comprehensive strategy for preventing 
catheter-UHODWHG LQIHFWLRQV  7KLV LQFOXGHV JRRG SUDFWLFH LQ FDULQJ IRU WKH SDWLHQW¶V
catheter hub and connection port, the use of an appropriate intravascular catheter 
site dressing regimen and using flush solutions to maintain the patency of the 
catheter.  
 
Choose the right dressing for insertion sites to minimise infection 
Following placement of a peripheral or central venous intravascular catheter, a 
dressing is used to protect the insertion site.  Because occlusive dressings trap 
moisture on the skin and provide an ideal environment for the rapid growth of local 
microflora, dressings for insertion sites must be permeable to water vapour.5 The two 
most common types of dressings used for insertion sites are sterile, transparent, 
semi-permeable polyurethane dressings coated with a layer of an acrylic adhesive 
µWUDQVSDUHQWGUHVVLQJV¶DQGJDX]HDQGWDSHGUHVVLQJV7UDQVSDUHQWGUHVVLQJVDUH
permeable to water vapour and oxygen and impermeable to microorganisms. 
 
Healthcare Infection Control Practices Advisory Committee (HICPAC) reviewed the 
evidence related to which type of dressing provided the greatest protection against 
infection,6 including the largest controlled trial of dressing regimens on peripheral 
venous catheters (PVCs),7 a meta-analysis comparing the risk of catheter related 
bloodstream infection (CR-BSI) using transparent versus gauze dressings8 and a 
Cochrane review.9 All concluded that the choice of dressing can be a matter of 
preference but if blood is leaking from the catheter insertion site, a gauze dressing 
might be preferred to absorb the fluid. We identified an updated Cochrane review,10 
which concluded that bloodstream infection was higher in the transparent 
polyurethane group when compared with gauze and tape. The included trials were 
graded low quality due to the small sample size and risk of bias. There was 
additional low quality evidence that demonstrated no difference between highly 
permeable polyurethane dressings and other polyurethane dressings in the 
prevention of catheter-related bloodstream infection. 
 
 Healthcare Infection Control Practices Advisory Committee (HICPAC) reviewed the 
evidence related to impregnated sponge dressings compared to standard dressings6 
and found two randomised controlled trials (RCTs) in adults that demonstrated 2% 
chlorhexidine-impregnated sponge dressings were associated with a significant 
reduction in CR-BSI.4,11   However, a meta-analysis that included eight RCTs found a 
reduction in exit site colonisation but no significant reduction in CR-BSI.8  In 
paediatric patients, two small RCTs found a reduction in catheter colonisation but not 
CR-BSI, and evidence of localised contact dermatitis when used for infants of very 
low birth weight.12,13 
 
We identified one further systematic review and meta-analysis, undertaken as part of 
a quality improvement collaborative, which synthesised the effects of the routine use 
of 2% chlorhexidine gluconate (CHG) impregnated sponge dressings in reducing 
centrally inserted CR-BSI.14 Five studies were included in the analysis, two of the five 
studies were in patients in haemo/oncological intensive care units (ICU), the 
remaining three were in surgical and medical ICU; four of the five studies were 
sponsored by the manufacturer of the product. The reviewers concluded that 2% 
CHG impregnated sponge dressings are effective in preventing CR-BSI (OR 0.43; 
95% CI 0.29 to 0.64) and catheter colonisation (OR 0.43; 95% CI 0.36. to 0.51).   
 
We identified an economic evaluation of the use of 2% CHG impregnated sponge 
dressings and the non-inferiority of dressing changes at three and seven days.16 
Authors concluded that the major cost avoided by the use of CHG sponge dressings 
and seven day rather than three day dressing changes was the increased length of 
stay of 11 days associated with CR-BSI. Chlorhexidine impregnated sponge 
dressings remained cost saving for any value where the cost per CR-BSI was 
>$4,400 and the baseline rate of CR-BSI was >0.35%.15 
 
We identified a further RCT of 2% CHG impregnated gel dressings compared with 
highly adhesive semi-permeable dressings or standard semi-permeable dressings for 
the prevention of CR-BSI in 1879 patients.4 In the CHG gel group the major catheter 
related infection rate was 67% lower (0.7 per 1,000 vs. 2.1 per 1,000 catheter-days; 
HR 0.328; 95% CI 0.174 to 0.619; p=0.0006) and the CR-BSI rate 60% lower (0.5 
per 1,000 vs. 1.3 per 1,000 catheter-days; HR 0.402; 95% Cl, 0.186 to 0.868; 
p=0.02) than with non-chlorhexidine dressings. Decreases were also noted in 
catheter colonisation and skin colonisation rates at catheter removal. Highly adhesive 
dressings decreased the detachment rate to 64.3% versus 71.9% (p <0.0001) and 
the number of dressings per catheter to two (one to four) versus three (one to five) (p 
< 0.0001) but increased skin colonisation (p <0.0001) and catheter colonisation (HR 
1.650; 95% Cl 1.21 to 2.26; p=0.0016) without influencing CR-BSI rates.4  
 
There have been no direct comparisons of the effectiveness and costs of CHG gel 
dressings impregnated with 2% CHG and 2%CHG sponge dressings. 
 
Updated Recommendation IVAD 20  
 
 ³&RQVLGHUWKHXVHRIDFKORUKH[LGLQHLPSUHJQDWHGVSRQJHRUJHO
dressings in adult patients with a central venous catheter as a strategy to 
UHGXFHFDWKHWHUUHODWHGEORRGVWUHDPLQIHFWLRQ´ 
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